6 July 2020 - - US-based pharmaceutical company Merck (NYSE: MRK), known as MSD outside the United States and Canada, TODAY announced

New analyses from the Phase 2b trial (NCT03272347) evaluating the safety and efficacy of islatravir, US-based pharmaceutical company Merck's (NYSE: MRK) investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTRO), in adults with HIV-1 infection who had not previously received antiretroviral treatment, the company said.

The first sub-analysis further characterized the tolerability and safety profile of islatravir in combination with doravirine (100 mg) through Week 48 across the three dose levels studied (0.25, 0.75, 2.25 mg).

The second sub-analysis demonstrated that participants who initiated treatment with islatravir and doravirine in combination with 3TC and switched to islatravir and doravirine maintained antiviral activity at Week 48 as measured by HIV-1 RNA